Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-03-31

FDA Approved: TRI-LUMA — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

FDA approved a supplemental application for Tri-Luma from Galderma Laboratories, L.P., likely updating labeling for this combination product containing fluocino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%)

Snippet

SUPPL AP for TRI-LUMA (FLUOCINOLONE ACETONIDE, HYDROQUINONE, AND TRETINOIN)